Journal: Genes & Diseases

Article Title: Chloride channel accessory 4 suppresses stem cell-like properties of colorectal cancer and enhances anti-PD-1 immunotherapy

doi: 10.1016/j.gendis.2025.101859

Figure Lengend Snippet: CLCA4 overexpression enhanced the therapeutic effect of anti-PD-1. (A) In vivo tumorigenicity assay in nude mice was performed to detect the therapeutic effect of CLCA4 overexpression combined with anti-PD-1 antibody. (B) Tumor growth curve was monitored from nude mice with different treatment groups. (C) Weights of tumors from nude mice with different treatments were detected. One-way ANOVA with Tukey's multiple comparisons test (mean ± standard deviation). (D) Analysis of the survival times of mice in each group ( n = 8 per group), and the experiment was terminated 60 days after tumor inoculation. Unpaired two-tailed t -test (mean ± standard deviation). (E) Immunofluorescence or immunohistochemistry staining was performed to detect the infiltration levels of CD8 + T cells, GZMB, Perforin + cells, Ki67 + , Bmi-1 + , and Oct4 + cells in tumors from different treatment groups. One-way ANOVA with Tukey's multiple comparisons test (mean ± standard deviation). (F) Hematoxylin-eosin staining of liver metastases in each group. (G) Quantitative analysis of the liver weight in each group. One-way ANOVA with Tukey's multiple comparisons test (mean ± standard deviation). (H) Quantitative analysis of the liver metastasis area/total liver area in each group. One-way ANOVA with Tukey's multiple comparisons test (mean ± standard deviation).

Article Snippet: After 7 days, mice were intraperitoneally treated with either an in vivo blocking antibody against mouse PD-1 (Clone: 29F.1A2, BioXcell, Cat# BP0273) or a rat IgG2a isotype control antibody (Clone: 2A3, BioXcell, Cat# BP0089).

Techniques: Over Expression, In Vivo, Tumorigenicity Assay, Standard Deviation, Two Tailed Test, Immunofluorescence, Immunohistochemistry, Staining

Journal: bioRxiv

Article Title: A multivalent peptide-polymer conjugate material mimics STING to therapeutically activate innate immune signaling

doi: 10.64898/2026.03.24.712780

Figure Lengend Snippet: ( A ) Mice were inoculated with 3×10 6 BPPNM cells IP and dosed with 20 μg of STING or Scr conjugate delivered by LNP IP at 10, 13, 16, and 19 days after inoculation. Omental tumor was collected on day 20 for analysis by flow cytometry. Groups included N = 5 mice. ( B ) Cell populations in tumor after treatment, displaying percentage of CD45 + cells made up by T cells (CD3 + ), CD8 + T cells, CD4 + T cells, NK cells (CD3 - NK1.1 + ), B cells (CD19 + ), Macrophages (F4/80 + ), DCs (CD11c + MHCII + ), and MDSCs (CD11b + Gr-1 hi ). Percentage of CD45 - cells made up by BPPNM cancer cells (GFP + ) are also displayed. ( C-D ) Polarization of Macrophages (F4/80 + ), showing MFI and representative distributions of ( C ) CD86 and ( D ) CD206. ( E ) Activation of DCs (CD11c + MHCII + ), showing MFI and representative distributions of CD86. ( F ) Expression of PD-1 on CD8 + T cells, showing percentage of cells that are PD-1 + and representative distributions of PD-1. P values computed with a one-way ANOVA followed by Tukey’s post-hoc test are displayed above each figure. All flow data is represented as mean ± SD. ( G ) Mice were inoculated with 3×10 6 BPPNM cells IP and dosed with 20 μg of STING or Scr conjugate delivered by LNP IP at 10, 13, 16, 19, and 22 days after inoculation. A subset of groups were additionally treated with 100 μg αPD-1 antibody at 11 and 17 days after inoculation. Groups included N = 6 (PBS, STING LNP, Scr LNP), N = 5 (STING LNP + αPD-1), or N = 4 (PBS + αPD-1, Scr LNP + αPD-1) mice. ( H ) Survival plot with P values determined by log(rank) (Mantel–Cox) test. ( I-K ) Tumor burden measured by IVIS, displaying ( I ) geometric mean ± SD bioluminescent intensity over the treatment period, ( J ) an image of the mouse with the median bioluminescent intensity from each group at the measurement following the end of treatment (day 24), and ( K ) individual mouse bioluminescent intensity values.

Article Snippet: In groups specified in figure captions, mice were also administered a 100 μg dose of anti-mouse PD-1 antibody (Bio X Cell #BE0273 InVivoMAb, Clone 29F.1A12) in 200 μL of 1× PBS on days 11 and 17 after tumor inoculation.

Techniques: Flow Cytometry, Activation Assay, Expressing